VNDA Insider Trading Activity and SEC Form 4 Filings
VNDA insider trading summary
Over the past 12 months, insiders at Vanda Pharmaceuticals Inc. (VNDA) reported 6 sales worth $2.8M by 6 insiders and 3 open-market purchases worth $38K by 1 insider on SEC Form 4. Net insider selling was $2.8M.
Latest VNDA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 5, 2026 | Charles Cliff Duncan | Insider | Buy | $22K (5,803 @ $3.80) |
| Nov 4, 2026 | Charles Cliff Duncan | Insider | Buy | $13K (3,447 @ $3.82) |
| Nov 3, 2026 | Charles Cliff Duncan | Insider | Buy | $3K (750 @ $3.80) |
| Mar 2, 2026 | Timothy Williams | SVP & General Counsel | Sell | $351K (42,434 @ $8.27) |
| Mar 2, 2026 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell | $351K (42,442 @ $8.27) |
| Mar 2, 2026 | Joakim Wijkstrom | SVP, Chief Marketing Officer | Sell | $255K (30,800 @ $8.27) |
| Mar 2, 2026 | Gunther Birznieks | SVP, Business Development | Sell | $351K (42,431 @ $8.27) |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos | President and CEO | Sell | $1.3M (156,235 @ $8.17) |
| Feb 23, 2026 | Tage Honore | Insider | Sell | $241K (30,000 @ $8.03) |
| Aug 7, 2025 | Mihael Hristos Polymeropoulos | President and CEO | Buy | $42K (10,000 @ $4.15) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.